Novel Cystosine deaminase fusion gene enhances the effect of radiation on breast cancer in bone by reducing tumor burden, osteolysis, and skeletal fracture

Clinical Cancer Research

Volumn 12, Issue 10, 2006, Pages 3168-3176

  Goblirsch, Michael ^a   Zwolak, Pawel ^a   Ramnaraine, Margaret L ^a   Pan, Weihong ^a   Lynch, Christine ^a   Alaei, Parham ^a   Clohisy, Denis R ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOSINE DEAMINASE; FLUCYTOSINE; HYBRID PROTEIN; NERVE GROWTH FACTOR RECEPTOR; ANTIMETABOLITE; PRODRUG; RADIOSENSITIZING AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE METASTASIS; BREAST CANCER; CANCER THERAPY; CONTROLLED STUDY; EXPERIMENTAL MODEL; FLOW CYTOMETRY; FRACTURE; FUSION GENE; GENE THERAPY; MOUSE; NONHUMAN; OSTEOLYSIS; PRIORITY JOURNAL; RADIATION; RADIATION DOSE; TUMOR VOLUME; ANIMAL; BIOSYNTHESIS; BONE TUMOR; CARCINOMA; DISEASE MODEL; EXPERIMENTAL NEOPLASM; FEMALE; GENETIC MARKER; GENETIC TRANSDUCTION; GENETICS; METABOLISM; METASTASIS; MULTIMODALITY CANCER THERAPY; PAIN; PATHOLOGY; RANDOMIZATION; TREATMENT OUTCOME;

ANIMALS; ANTIMETABOLITES; BONE NEOPLASMS; CARCINOMA; COMBINED MODALITY THERAPY; CYTOSINE DEAMINASE; DISEASE MODELS, ANIMAL; FEMALE; FLUCYTOSINE; FRACTURES, BONE; GENE THERAPY; GENETIC MARKERS; MAMMARY NEOPLASMS, ANIMAL; MICE; OSTEOLYSIS; PAIN; PRODRUGS; RADIATION-SENSITIZING AGENTS; RANDOM ALLOCATION; RECEPTOR, NERVE GROWTH FACTOR; TRANSDUCTION, GENETIC; TREATMENT OUTCOME;

EID: 33744831456     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-05-2729     Document Type: Article

References (43)

1. Lawrence TS, Tepper JE, Blackstock AW. Fluoropyrimidine-radiation interactions in cells and tumors. Semin Radiat Oncol 1997;7:260-6.
2. Longley DB, Harkin DP, Johnston PG. 5-Fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 2003;3:330-8.
3. Grem JL. Mechanisms of action and modulation of fluorouracil. Semin Radiat Oncol 1997;7:249-59.
4. Ramnaraine M, Pan W, Goblirsch M, et al. Direct and bystander killing of sarcomas by novel cytosine deaminase fusion gene. Cancer Res 2003;63: 6847-54.
5. Xia K, Liang D, Tang A, et al. A novel fusion suicide gene yeast CDglyTK plays a role in radio-gene therapy of nasopharyngeal carcinoma. Cancer Gene Ther 2004;11:790-6.
6. Freytag SO, Paielli D, Wing M, et al. Efficacy and toxicity of replication-competent adenovirus-mediated double suicide gene therapy in combination with radiation therapy in an orthotopic mouse prostate cancer model. Int J Radiat Oncol Biol Phys 2002;54:873-85.
7. Freytag SO, Stricker H, Pegg J, et al. Phase I study of replication-competent adenovirus-mediated double-suicide gene therapy in combination with conventional-dose three-dimensional conformal radiation therapy for the treatment of newly diagnosed, intermediate- to high-risk prostate cancer. Cancer Res 2003;63: 7497-506.
8. Li S, Yu B, An P, et al. Combined liposome-mediated cytosine deaminase gene therapy with radiation in killing rectal cancer cells and xenografts in athymic mice. Clin Cancer Res 2005;11:3574-8.
9. Cunningham C, Nemunaitis J. A phase I trial of genetically modified Salmonella typhimurium expressing cytosine deaminase (TAPET-CD, VNP20029) administered by intratumoral injection in combination with 5-fluorocytosine for patients with advanced or metastatic cancer. Protocol no.: CL-017. Version: April 9, 2001. Hum Gene Ther 2001;12:1594-6.
10. Gupta VK, Park JO, Jaskowiak NT, et al. Combined gene therapy and ionizing radiation is a novel approach to treat human esophageal adenocarcinoma. Ann Surg Oncol 2002;9:500-4.
11. Liu Y, Ye T, Maynard J, Akbulut H, Deisseroth A. Engineering conditionally replication-competent adenoviral vectors carrying the cytosine deaminase gene increases the infectivity and therapeutic effect for breast cancer gene therapy. Cancer Gene Ther 2006;13:346-56.
12. Pandha HS, Martin LA, Rigg A, et al. Genetic pro-drug activation therapy for breast cancer: a phase I clinical trial of erbB-2-directed suicide gene expression. J Clin Oncol 1999;17:2180-9.
13. Michigami T, Hiraga T, Williams PJ, et al. The effect of the bisphosphonate ibandronate on breast cancer metastasis to visceral organs. Breast Cancer Res Treat 2002;75:249-58.
14. Lipton ARL, Kohno N, Coleman R, Zheng M, Milton S. Zoledronic acid provides long-term reduction of bone pain in patients with bone metastases secondary to breast cancer In: Fifth International Conference on Cancer-Induced Bone Disease; Davos, Switzerland; 2005. p. S29-30.
15. Ali SM, Harvey HA, Lipton A. Metastatic breast cancer: overview of treatment. Clin Orthop 2003; (415 Suppl):S132-7. Review
16. Ratanatharathorn V, Powers WE, Moss WT, Perez CA. Bone metastasis: review and critical analysis of random allocation trials of local field treatment. Int J Radiat Oncol Biol Phys 1999;44:1-18.
17. Tong D, Gillick L, Hendrickson FR. The palliation of symptomatic osseous metastases: final results of the study by the Radiation Therapy Oncology Group. Cancer 1982;50:893-9.
18. Rasmusson B, Vejborg I, Jensen AB, et al. Irradiation of bone metastases in breast cancer patients: a randomized study with 1 year follow-up. Radiother Oncol 1995;34:179-84.
19. Goblirsch M, Lynch C, Mathews W, Manivel JC, Mantyh PW, Clohisy DR. Radiation treatment decreases bone cancer pain through direct effect on tumor cells. Radiat Res 2005;164:400-8.
20. Goblirsch M, Mathews W, Lynch C, et al. Radiation treatment decreases bone cancer pain, osteolysis and tumor size. Radiat Res 2004;161:228-34.
21. Lewis VA, Basso L, Blake N, et al. Human nerve growth factor receptor and cytosine deaminase fusion genes. Hum Gene Ther 2003;14:1009-16.
22. Senter PD, Su PC, Katsuragi T, et al. Generation of 5-fluorouracil from 5-fluorocytosine by monoclonal antibody-cytosine deaminase conjugates. Bioconjug Chem 1991;2:447-51.
23. Durand RE. Cure, regression and cell survival: a comparison of common radiobiological endpoints using an in vitro tumour model. Br J Radiol 1975;48: 556-71.
24. Lutz W, Winston KR, Maleki N. A system for stereotactic radiosurgery with a linear accelerator. Int J Radiat Oncol Biol Phys 1988;14:373-81.
25. Honore P, Luger NM, Sabino MA, et al. Osteoprotegerin blocks bone cancer-induced skeletal destruction, skeletal pain and pain-related neurochemical reorganization of the spinal cord. Nat Med 2000;6:521-8.
26. Sevcik MA, Luger NM, Mach DB, et al. Bone cancer pain: the effects of the bisphosphonate alendronate on pain, skeletal remodeling, tumor growth and tumor necrosis. Pain 2004;111:169-80.
27. Luger NM, Sabino MA, Schwei MJ, et al. Efficacy of systemic morphine suggests a fundamental difference in the mechanisms that generate bone cancer vs inflammatory pain. Pain 2002;99:397-406.
28. Luger NM, Honore P, Sabino MA, et al. Osteoprotegerin diminishes advanced bone cancer pain. Cancer Res 2001;61:4038-47.
29. Fox A, Medhurst S, Courade JP, et al. Anti-hyperalgesic activity of the cox-2 inhibitor lumiracoxib in a model of bone cancer pain in the rat. Pain 2004;107: 33-40.
30. Medhurst SJ, Walker K, Bowes M, et al. A rat model of bone cancer pain. Pain 2002;96:129-40.
31. 19F nuclear magnetic resonance spectroscopy pharmacokinetics. J Clin Oncol 1990;8:1868-73.
32. Byfield JE. Useful interactions between 5-fluorouracil and radiation in man: 5-fluorouracil as a radio-sensitizer. In: Hill BT, Bellamy AS, editors. Antitumor drug-radiation interactions. Boca Raton (FL): CRC Press; 1990. p. 87-105.
33. Byfield JE, Calabro-Jones P, Klisak I, Kulhanian F. Pharmacologic requirements for obtaining sensitization of human tumor cells in vitro to combined 5-fluorouracil or ftorafur and X rays. Int J Radiat Oncol Biol Phys 1982;8:1923-33.
34. Sabino MA, Luger NM, Mach DB, Rogers SD, Schwei MJ, Mantyh PW. Different tumors in bone each give rise to a distinct pattern of skeletal destruction, bone cancer-related pain behaviors and neurochemical changes in the central nervous system. Int J Cancer 2003;104:550-8.
35. Ramnaraine M, Pan W, Clohisy DR. Osteoclasts direct bystander killing of cancer cells in vitro. Bone 2006;38:4-12.
36. Huber BE, Austin EA, Richards CA, Davis ST, Good SS. Metabolism of 5-fluorocytosine to 5-fluorouracil in human colorectal tumor cells transduced with the cytosine deaminase gene: significant antitumor effects when only a small percentage of tumor cells express cytosine deaminase. Proc Natl Acad Sci U S A 1994;91:8302-6.
37. Zhang Z, Shirakawa T, Hinata N, et al. Combination with CD/5-FC gene therapy enhances killing of human bladder-cancer cells by radiation. J Gene Med 2003;5:860-7.
38. Hallahan DE, Mauceri HJ, Seung LP, et al. Spatial and temporal control of gene therapy using ionizing radiation. Nat Med 1995;1:786-91.
39. Marples B, Scott SD, Hendry JH, Embleton MJ, Lashford LS, Margison GP. Development of synthetic promoters for radiation-mediated gene therapy. Gene Ther 2000;7:511-7.
40. Kufe D, Weichselbaum R. Radiation therapy: activation for gene transcription and the development of genetic radiotherapy-therapeutic strategies in oncology. Cancer Biol Ther 2003;2:326-9.
41. Staba MJ, Mauceri HJ, Kufe DW, Hallahan DE, Weichselbaum RR. Adenoviral TNF-α gene therapy and radiation damage tumor vasculature in a human malignant glioma xenograft. Gene Ther 1998; 5:293-300.
42. Mauceri HJ, Hanna NN, Wayne JD, Hallahan DE, Hellman S, Weichselbaum RR. Tumor necrosis factor α (TNF-α) gene therapy targeted by ionizing radiation selectively damages tumor vasculature. Cancer Res 1996;56:4311-4.
43. Weichselbaum RR, Kufe DW, Hellman S, et al. Radiation-induced tumour necrosis factor-α expression: clinical application of transcriptional and physical targeting of gene therapy. Lancet Oncol 2002; 3:665-71.